|
NCT05242172
|
THE RELATIONSHIP OF CRP/ALBUMIN RATIO LEVEL AND PROGNOSIS IN PREGNANT COVID-19 PATIENTS |
Active, not recruiting |
|
Jan/15/2022 |
Feb/28/2022 |
- Alternative id - 14/12/2021-2021/10-19
- Interventions - Diagnostic Test: CRP/Albumin ratio
- Study type - Observational
- Study results - No Results Available
- Locations - Adıyaman Training and Research Hospital, Adıyaman, Turkey
- Study designs - Observational Model: Cohort|Time Perspective: Retrospective
- Enrollment - 127
- Age - 18 Years to 65 Years (Adult, Older Adult)
- Outcome measures - CRP/Albumin ratio
|
|
NCT05286268
|
The Role of Ischemia Modified Albumin in Patients With COVID-19 |
Not yet recruiting |
|
Mar/01/2022 |
Jul/01/2022 |
- Alternative id - 24918
- Interventions - Diagnostic Test: Ischemia Modified Albumin
- Study type - Observational
- Study results - No Results Available
- Locations -
- Study designs - Observational Model: Cohort|Time Perspective: Prospective
- Enrollment - 194
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Hospitalization outcome
|
|
NCT04576728
|
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19 |
Active, not recruiting |
Phase 2 |
Oct/06/2020 |
Jul/01/2021 |
- Alternative id - 998
- Interventions - Drug: Trimodulin|Other: Placebo (human albumin 1%)
- Study type - Interventional
- Study results - No Results Available
- Locations - Investigational site # 5503, Porto Alegre, Brazil|Investigational site # 5502, Santo André, Brazil|Investigational site # 5505, Santo André, Brazil|Investigational site # 5501, São Paulo, Brazil|Investigational site # 3304, Paris, France|Investigational Site # 3301, Paris, France|Investigational site # 3305, Saint-Étienne, France|Investigational site # 0707, Kemerovo, Russian Federation|Investigational site # 0709, Krasnoyarsk, Russian Federation|Investigational site # 0702, Moscow, Russian Federation|Investigational site # 0706, Moscow, Russian Federation|Investigational site # 0711, Moscow, Russian Federation|Investigational Site # 0704, Moscow, Russian Federation|Investigational site # 0708, Moscow, Russian Federation|Investigational site # 0701, Saint Petersburg, Russian Federation|Investigational Site # 3401, Barcelona, Spain|Investigational Site # 3402, Madrid, Spain
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 164
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Clinical detoriation rate|28-day all-cause mortality rate|Clinical deterioration rate|28-days all-cause mortality rate on day 29|Time to clinical deterioration|Time to Mortality|Proportion of subjects in each of the 9-categories of the ordinal scale|Time to clinical improvement|Proportion of subjects with score ≤2|Days on IMV|Days without oxygen supply|Time to discontinuation from any form of oxygen supply|Proportion of subjects without any form of oxygen supply|Hospital-free-days|SARS-CoV-2 status|Adverse events (AEs), treatment-emergent AEs (TEAEs), AEs of special interest, infusional TEAEs|TEAEs|SAEs|Dose modifications|Time to recovery|Change over time in ECG parameters|Change over time in vital signs
|
|
NCT04390503
|
Convalescent Plasma for Early Treatment of COVID-19 |
Recruiting |
Phase 2 |
Mar/12/2021 |
Apr/01/2022 |
- Alternative id - AAAT0052
- Interventions - Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Control (albumin 5%)
- Study type - Interventional
- Study results - No Results Available
- Locations - National Institute of Infectious Diseases Evandro Chagas (INI), Rio de Janeiro, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 150
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Rate of Severe Disease|Rate of measurable anti-SARS-CoV-2 titers|Rate of SARS-CoV-2 PCR Positivity|Duration of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA
|
|
NCT04405310
|
Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial |
Completed |
Phase 2 |
May/20/2020 |
Dec/10/2020 |
- Alternative id - DI/20/201/04/19
- Interventions - Biological: Convalescent Plasma of patients with COVID-19|Other: placebo (hartmann plus albumine)
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Nava de Alta Especialidad, Mexico City, Mexico|Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
- Enrollment - 42
- Age - 18 Years to 70 Years (Adult, Older Adult)
- Outcome measures - Death|Lenth of stay ICU|Days of Mechanical Ventilation|Suplemental Oxigen support|Viral Load by RT-PCR|Inflamatory biomarkers|SOFA (sequencial Organ Failure Assesment)
|
|
NCT04288102
|
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19) |
Completed |
Phase 2 |
Mar/05/2020 |
Jul/09/2020 |
- Alternative id - 2020-013-D
- Interventions - Biological: UC-MSCs|Biological: Saline containing 1% Human serum albumin（solution without UC-MSCs）
- Study type - Interventional
- Study results - No Results Available
- Locations - General Hospital of Central Theater Command, Wuhan, Hubei, China|Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 100
- Age - 18 Years to 75 Years (Adult, Older Adult)
- Outcome measures - Change in lesion proportion (%) of full lung volume from baseline to day 28.|Change in lesion proportion (%) of full lung volume from baseline to day 10 and 90|Change in consolidation lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Change in ground-glass lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Pulmonary fibrosis - related morphological features in CT scan at day 90 a. cord-like shadow b. honeycomb-like shadows c. interlobular septal thickening d. intralobular interstitial thickening e. pleural thickening|Lung densitometry: Change in total voxel 'weight' in lesion area voxel 'weight'=voxel density (in HU) × voxel volume (in voxel)|Lung densitometry: volumes histogram of lung density distribution (<-750, -750~-300, -300~50, >50) at day 10, 28 and 90.|Time to clinical improvement in 28 days.|Oxygenation index( PaO2/FiO2)|Duration of oxygen therapy(days)|Blood oxygen saturation|6-minute walk test|Maximum vital capacity (VCmax)|Diffusing Capacity (DLCO)|mMRC (Modified Medical Research Council) dyspnea scale|Changes of absolute lymphocyte counts and subsets from baseline to day 6, 10, 28 and 90.|Changes of cytokine/chemokine levels from baseline to day 6, 10, 28 and 90.|Adverse events|Serious adverse events|All-cause mortality
|
